NICE backs two new breast cancer drugs for NHS use
pharmaphorum
JULY 14, 2022
The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use. NICE estimates that around 2,800 people are eligible for treatment with Piqray plus fulvestrant.
Let's personalize your content